Treatment of Stroke at a Delayed Timepoint with a Repurposed Drug Targeting Sigma 1 Receptors

Keyphrases

• Cell Proliferation 100%
• Transient Middle Cerebral Artery Occlusion (tMCAO) 100%
• Drug Target 100%
• Stroke Treatment 100%
• Sigma-1 Receptor 100%
• Drug Repurposing 100%
• Astrogliosis 50%
• Brain-derived Neurotrophic Factor 50%
• Inflammation 50%
• Infarct Size 50%
• Male Rats 50%
• Subventricular Zone 50%
• Molecular Chaperone 50%
• Dentate Gyrus 50%
• Oral Administration 50%
• Cerebral Cortex 50%
• Stroke Outcome 50%
• Blood-brain Barrier 50%
• Neurological Function 50%
• Single Oral Dose 50%
• In Vitro Study 50%
• Infarct 50%
• Sigma-1 Receptor Agonist 50%
• Stroke Rehabilitation 50%
• Subacute Phase 50%
• Microgliosis 50%
• Antitussive 50%
• Infarct Expansion 50%
• Serum BDNF 50%
• Oxolamine Citrate 50%
• Blood Clotting 50%
• BDNF Secretion 50%

Neuroscience

• Brain-Derived Neurotrophic Factor 100%
• Sigma 1 Opiate Receptor 100%
• Cerebrovascular Accident 100%
• In Vitro 50%
• Cell Proliferation 50%
• Middle Cerebral Artery 50%
• Astrogliosis 25%
• Chaperone 25%
• Dentate Gyrus 25%
• Blood Brain Barrier 25%
• Subventricular Zone 25%
• Cerebral Cortex 25%
• Gliosis 25%
• Receptor Agonists 25%
• Coagulation System 25%
• Antitussives 25%

Pharmacology, Toxicology and Pharmaceutical Science

• Drug Delivery System 100%
• Sigma 1 Opiate Receptor 100%
• Cerebrovascular Accident 100%
• Oxeladin 100%
• Brain Derived Neurotrophic Factor 57%
• Rat 57%
• Infarction 42%
• Middle Cerebral Artery Occlusion 28%
• Inflammation 14%
• Chaperone 14%
• Astrocytosis 14%
• Gliosis 14%
• Receptor Agonist 14%
• Blood-Brain Barrier 14%
• Oral Administration 14%